CLINICAL TRIALS PROFILE FOR SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00121641 ↗ | Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Completed | AstraZeneca | Phase 3 | 2005-07-01 | The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise |
| NCT00121667 ↗ | Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone | Completed | AstraZeneca | Phase 3 | 2005-08-01 | The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone |
| NCT00327015 ↗ | A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Completed | AstraZeneca | Phase 3 | 2006-05-01 | The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone |
| NCT00575588 ↗ | 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period | Completed | Bristol-Myers Squibb | Phase 3 | 2007-12-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin. |
| NCT00575588 ↗ | 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period | Completed | AstraZeneca | Phase 3 | 2007-12-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin. |
| NCT00661362 ↗ | Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes | Completed | Bristol-Myers Squibb | Phase 3 | 2008-06-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise. |
| NCT00661362 ↗ | Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes | Completed | AstraZeneca | Phase 3 | 2008-06-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Condition Name
Clinical Trial Locations for SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Sponsor Name
